Workflow
Autobio(603658)
icon
Search documents
安图生物(603658) - 安图生物关于会计政策变更的公告
2025-04-17 09:15
证券代码:603658 证券简称:安图生物 公告编号:2025-026 郑州安图生物工程股份有限公司 关于会计政策变更公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、本次会计变更概述 (一)会计政策变更的原因 2024年12月,财政部发布《企业会计准则解释第18号》(财会〔2024〕24号), 规定对不属于单项履约义务的保证类质量保证产生的预计负债,应当按确定的金 额计入"主营业务成本"和"其他业务成本"等科目,该解释规定自印发之日起施行, 允许企业自发布年度提前执行。 (二)变更前采用的会计政策 本次会计政策变更前,公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 (三)变更后采用的会计政策 本次会计政策变更后,公司将执行《企业会计准则解释第18号》的相关规定。 1 本次会计政策变更对公司财务状况、经营成果和现金流量不会产生重大影 响。 本次会计政策变更系公司依据中华人民共和国财政部发布的相关企业会 计准则解释而进行 ...
安图生物(603658) - 关于会计师事务所2024年度履职情况评估报告
2025-04-17 09:15
郑州安图生物工程股份有限公司 关于会计师事务所 2024 年度履职情况的评估报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求,公司对中 勤万信会计师事务所(特殊普通合伙)(以下简称"中勤万信")2024 年审计过程 中的履职情况进行评估。经评估,公司认为中勤万信资质等方面合规有效,履职保 持独立性,勤勉尽责,公允表达意见,具体情况如下: 一、资质条件 中勤万信系 2013 年 12 月根据财政部《关于推动大中型会计师事务所采用特殊普 通合伙组织形式的暂行规定》由原中勤万信会计师事务所有限公司转制而成的特殊 普通合伙企业,2013 年 12 月 11 日经北京市财政局批准同意(京财会许可[2013]0083 号),2013 年 12 月 13 日取得北京市工商行政管理局西城分局核发的《合伙企业营 业执照》。注册地址在北京市西城区西直门外大街 112 号阳光大厦 10 层。中勤万信 具有证监会和财政部颁发的证券期货相关业务审计资格。截至 2024 年末,中勤万信 拥有合伙人 76 人、注册会计师 393 名,签署过证券服务业 ...
安图生物(603658) - 安图生物2024年度募集资金存放与使用情况鉴证报告
2025-04-17 09:15
郑州安图生物工程股份有限公司 2024 年度募集资金存放与使用情况 鉴证报告 勤信专字【2025】第 0640 号 | 内容 | 页次 | | --- | --- | | 鉴证报告 | 1-2 | | 附件: | | | 郑州安图生物工程股份有限公司董事会关于 | 3-34 | | 2024 年度募集资金存放与使用情况的专项报告 | | 目录 中勤万信会计师事务所(特殊普通合伙) 地址:北京西直门外大街 112 号阳光大厦 10 层 电话:(86-10)68360123 传真:(86-10)68360123-3000 邮编:100044 郑州安图生物工程股份有限公司 2024 年度募集资金存放与使用情况鉴证报告 勤信专字【2025】第 0640 号 郑州安图生物工程股份有限公司全体股东: 我们接受委托,审核了后附的郑州安图生物工程股份有限公司(以下简称"贵公司") 管理层编制的《关于 2024 年度募集资金存放与使用情况的专项报告》(以下简称"募 集资金专项报告")。 一、管理层的责任 郑州安图生物工程股份有限公司管理层的责任是按照中国证券监督管理委员会发 布的《上市公司监管指引第 2 号——上市公司募集资金 ...
安图生物(603658) - 安图生物关于召开2024年年度股东大会的通知
2025-04-17 09:15
证券代码:603658 证券简称:安图生物 公告编号:2025-028 郑州安图生物工程股份有限公司 关于召开 2024 年年度股东大会的通知 重要内容提示: 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年年度股东大会 召开的日期时间:2025 年 5 月 8 日 14 点 00 分 召开地点:公司会议室 (五) 网络投票的系统、起止日期和投票时间。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 股东大会召开日期:2025年5月8日 本次股东大会采用的网络投票系统:上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人:董事会 (三) 投票方式:本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统:上海证券交易所股东大会网络投票系统 网络投票起止时间:自 2025 年 5 月 8 日 至 2025 年 5 月 8 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段,即 9:15-9:25, ...
安图生物(603658) - 安图生物第五届监事会第四次会议决议公告
2025-04-17 09:15
证券代码:603658 证券简称:安图生物 公告编号:2025-021 郑州安图生物工程股份有限公司 第五届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、 监事会会议召开情况 郑州安图生物工程股份有限公司(以下简称"安图生物"或"公司")第五届监 事会第四次会议的会议通知和材料于2025年4月6日以电子邮件方式发出,会议于 2025年4月16日在公司会议室以现场表决方式召开,会议应参加监事3名,实际参 加监事3名。会议由公司监事会主席韩明明先生主持。 会议的召集和召开程序符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定,会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议,以记名投票表决方式一致通过以下议案: 1. 审议通过《2024年度监事会工作报告》 表决情况:3票同意,0票反对,0票弃权。 本项议案尚需提交公司2024年年度股东大会审议批准。 2. 审议通过《2024年度财务决算报告》 表决情况:3票同意,0票反对,0票弃 ...
安图生物(603658) - 安图生物第五届董事会第四次会议决议公告
2025-04-17 09:15
证券代码:603658 证券简称:安图生物 公告编号:2025-020 会议的召集和召开程序符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定,会议形成的决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议,以记名投票表决方式一致通过以下议案: 1. 审议通过《2024年度总经理工作报告》 表决情况:11票同意,0票反对,0票弃权。 郑州安图生物工程股份有限公司 第五届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、董事会会议召开情况 郑州安图生物工程股份有限公司(以下简称"安图生物"或"公司")第五 届董事会第四次会议的会议通知和材料于2025年4月6日以电子邮件方式发出,会 议于2025年4月16日在公司会议室以现场和通讯相结合的方式召开,会议应参加董 事11名,实际参加表决董事11名(其中董事苗拥军、张亚循、付光宇、独立董事 袁华刚以通讯方式参加会议)。会议由公司董事长苗拥军先生主持,公司监事和 部分高级管理人员列席了本次会议。 2. ...
安图生物(603658) - 2025 Q1 - 季度财报
2025-04-17 09:15
Financial Performance - The company's operating revenue for Q1 2025 was CNY 995,933,663.32, representing a decrease of 8.56% compared to CNY 1,089,195,256.05 in the same period last year[4] - Net profit attributable to shareholders was CNY 269,880,235.57, down 16.76% from CNY 324,212,004.34 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.47, reflecting a decrease of 16.07% compared to CNY 0.56 in the previous year[5] - The weighted average return on equity decreased by 0.65 percentage points to 3.09% from 3.74%[5] - Total operating revenue for Q1 2025 was ¥995,933,663.32, a decrease of 8.6% compared to ¥1,089,195,256.05 in Q1 2024[19] - Net profit for Q1 2025 was ¥273,079,722.47, a decline of 17.0% from ¥328,699,468.29 in Q1 2024[20] - The company reported a total comprehensive income of ¥273,067,610.47 for Q1 2025, down from ¥328,712,789.76 in Q1 2024[21] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 49.35%, amounting to CNY 166,338,458.26, primarily due to a significant decline in sales receipts[8] - Cash received from sales of goods and services in Q1 2025 was ¥1,121,264,719.60, a decrease of 10.6% from ¥1,254,041,270.41 in Q1 2024[24] - The net cash flow from operating activities was $166,338,458.26, a decrease of 49.3% compared to $328,402,122.27 in the previous period[25] - The ending balance of cash and cash equivalents was $219,525,703.08, down from $1,077,430,057.76 year-over-year[27] - The company's cash and cash equivalents decreased to RMB 232,830,899.63 from RMB 465,373,123.02[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,968,031,676.54, an increase of 0.78% from CNY 11,875,065,943.97 at the end of the previous year[5] - Total liabilities decreased to ¥2,998,174,827.59 in Q1 2025 from ¥3,183,270,091.04 in Q1 2024, a reduction of 5.8%[17] - Accounts receivable stood at RMB 1,096,610,904.01, slightly down from RMB 1,138,995,430.17[15] - Inventory increased to RMB 1,170,654,495.92 from RMB 1,153,089,499.27[15] Shareholder Information - Shareholders' equity attributable to the parent company increased by 3.02% to CNY 8,876,936,827.16 from CNY 8,616,530,318.04[5] - The total number of ordinary shareholders at the end of the reporting period was 34,163[10] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 57.65% of the shares, totaling 329,445,773 shares[10] - The company has no related party relationships among the top ten shareholders, ensuring independent ownership structures[12] Future Outlook and Strategy - The company is focusing on expanding its market presence and enhancing product development strategies[12] - Future guidance and performance outlook will be provided in subsequent earnings calls[12] Expenses - Total operating costs for Q1 2025 were ¥746,443,403.96, down 4.0% from ¥777,943,233.44 in Q1 2024[19] - Research and development expenses for Q1 2025 were ¥130,563,085.75, down 13.7% from ¥151,149,747.29 in Q1 2024[20] - Cash outflow for purchasing goods and services was $373,420,356.81, up from $342,713,332.33 in the previous period[25] - Cash paid to employees increased to $476,776,379.07 from $434,312,784.10 year-over-year[25] - Cash paid for taxes decreased to $72,647,267.29 from $109,465,529.66 in the previous period[25] - Cash paid for other operating activities was $121,760,849.59, slightly up from $117,221,314.12 year-over-year[25]
安图生物(603658) - 2024 Q4 - 年度财报
2025-04-17 09:15
Financial Performance - The company's operating revenue for 2024 reached ¥4,471,202,509.22, a slight increase of 0.62% compared to ¥4,443,655,727.69 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥1,194,451,909.72, reflecting a decrease of 1.89% from ¥1,217,438,887.27 in 2023[25]. - The net cash flow from operating activities decreased by 10.92% to ¥1,309,282,741.12 in 2024, down from ¥1,469,855,864.22 in 2023[25]. - The total assets of the company increased by 2.78% to ¥11,875,065,943.97 in 2024, compared to ¥11,554,058,269.37 in 2023[25]. - The basic earnings per share for 2024 was ¥2.07, a decrease of 1.43% from ¥2.10 in 2023[26]. - The weighted average return on equity decreased to 13.92% in 2024 from 14.92% in 2023, a reduction of 1 percentage point[26]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥1,098,820,497.48, down 7.30% from ¥1,185,306,158.13 in 2023[25]. - The company reported a decrease in operating costs to CNY 1,546,573,971.03, down 0.84% from the previous year[105]. - The company’s R&D expenses increased by 11.55% to CNY 731,932,785.27, indicating a commitment to innovation and product development[105]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of RMB 1.26 per share, totaling RMB 719,995,207.68, which represents 60.28% of the net profit attributable to shareholders for the reporting period[6]. - The total amount for cash dividends and share repurchases is RMB 1,156,354,571.73, accounting for 96.81% of the net profit attributable to shareholders for the year[6]. - The company has implemented a share repurchase program totaling RMB 436,359,364.05, which includes transaction costs[6]. Research and Development - The company achieved R&D investment of CNY 73.19 million, accounting for 16.37% of total revenue[36]. - The company has established a comprehensive technical R&D system with multiple centers, enhancing its capability in cutting-edge technology and product development[72]. - The company is focusing on enhancing its immunodiagnostic product line, with multiple new antibody calibrators and test kits set for approval in June 2024[131]. - The company is actively pursuing regulatory approvals for new products, which is crucial for maintaining competitive advantage in the healthcare market[60][81]. Product Development and Innovation - The company successfully developed 144 new reagent products, enhancing its product series and brand influence[37]. - The AutoChem B2000 and AutoChem B800 series fully automated biochemical analyzers were launched, providing flexible solutions for large medical laboratories[38]. - The company launched three gene sequencers (Sikun 2000, Sikun 1000, Sikun 500) and an automated pathogen analysis system (APAS) in 2024[40]. - The company has developed a fully automated microbial mass spectrometry detection system, Autof ms series, which is widely used in clinical and public health applications[82]. - The company is expanding its product line with a focus on biochemical detection and immunodiagnostics, indicating a strategic move to capture a larger market share in these segments[57][60][79]. Market Trends and Industry Insights - The global in vitro diagnostic (IVD) market is projected to reach $109.2 billion in 2024, with a stable growth forecast to $140 billion by 2027[45]. - The Chinese IVD market reached ¥118.5 billion in 2023, with expectations to exceed ¥120 billion in 2024, driven by increasing health awareness and early diagnosis needs[50]. - The immunodiagnostics segment is the largest in China, with a market size of ¥50.3 billion in 2023, growing 13% year-on-year, accounting for 42.45% of the market share[51]. - The molecular diagnostics market in China reached ¥14.8 billion in 2023, representing 12.49% of the market, and is one of the fastest-growing segments due to its high sensitivity and specificity[51]. Governance and Compliance - The board of directors and management confirm the authenticity, accuracy, and completeness of the annual report[3]. - The company has not violated decision-making procedures for external guarantees[8]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting investment risks[7]. - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations to maximize shareholder interests[166]. Financial Management and Capital Structure - The company reported a foreign exchange swap investment with a fair value change gain of RMB 3.61 million during the reporting period[147]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to CNY 990.44 million[184]. - The company is actively managing its capital structure, including proposals to adjust registered capital and amend its articles of association[188]. Employee and Workforce Management - The total number of employees in the company is 5,773, with 2,580 in major subsidiaries[199]. - The company has established a comprehensive compensation and benefits system, combining fixed and variable pay based on performance[200]. - The educational background of employees includes 295 with below college education, 1,403 with college diplomas, 2,914 with bachelor's degrees, and 1,161 with master's degrees or higher[199]. Strategic Partnerships and Market Expansion - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[177]. - The company plans to enter two new international markets by Q2 2024, aiming for a 10% contribution to overall revenue[177]. - The company is focused on expanding its market presence through strategic partnerships and board appointments in various related companies[175].
安图生物(603658) - 安图生物2024年度利润分配预案公告
2025-04-17 09:15
2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 每股分配比例:A 股每股派发现金红利 1.26 元(含税)。 本次利润分配以实施权益分派股权登记日登记的总股本为基数,具体 日期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股 本发生变动的,拟维持分配总额不变,相应调整每股派发现金红利。 证券代码:603658 证券简称:安图生物 公告编号:2025-022 郑州安图生物工程股份有限公司 本次利润分配不送股、不进行资本公积转增股本。如在本公告披露之日起至 实施权益分派股权登记日期间,因可转债转股/回购股份/股权激励授予股份回购 注销/重大资产重组股份回购注销等致使公司总股本发生变动的,公司拟维持分 配总额不变,相应调整每股分配金额。如后续总股本发生变化,将另行公告具体 调整情况。 本次利润分配预案尚需提交公司 2024 年年度股东大会审议。 项目 2024年度 2023年度 2022年度 现金分红总额(元) 719,995,207.68 608,800,164.62 ...
安图生物:2025年第一季度净利润2.7亿元,同比下降16.76%
news flash· 2025-04-17 08:54
安图生物(603658)公告,2025年第一季度营收为9.96亿元,同比下降8.56%;净利润为2.7亿元,同比 下降16.76%。 ...